PDCD1 and cancer: TGF-ß1 overexpression and signaling in cancer has been associated with poor prognosis and resistance to immune checkpoint inhibitors, including anti-programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) therapies (6, 7).